A Multicenter, Randomized, Controlled, Open-label Study to Evaluate the Cognitive Development Effects and Safety, and Pharmacokinetics of Adjunctive Rufinamide Treatment in Pediatric Subjects 1 to Less Than 4 Years of Age With Inadequately Controlled Lennox-Gastaut Syndrome.

Trial Profile

A Multicenter, Randomized, Controlled, Open-label Study to Evaluate the Cognitive Development Effects and Safety, and Pharmacokinetics of Adjunctive Rufinamide Treatment in Pediatric Subjects 1 to Less Than 4 Years of Age With Inadequately Controlled Lennox-Gastaut Syndrome.

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Apr 2018

At a glance

  • Drugs Rufinamide (Primary) ; Antiepileptic drugs
  • Indications Lennox-Gastaut syndrome; Seizures
  • Focus Registrational; Therapeutic Use
  • Acronyms Study 303
  • Sponsors Eisai Inc
  • Most Recent Events

    • 27 Apr 2018 Results of a post hoc analysis, presented at the 70th Annual Meeting of the American Academy of Neurology
    • 27 Apr 2018 Results from NCT01151540, NCT01405053, NCT01146951 and 2 other studies, presented at the 70th Annual Meeting of the American Academy of Neurology
    • 05 Dec 2016 Primary endpoint has not been met. (Change in Child Behavior Checklist (CBCL) Total Problems Score), as reported in an Eisai Co Ltd media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top